Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Bone Marrow Transplant ; 28(2): 187-96, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11509937

ABSTRACT

Intravenous immunoglobulin is approved for use in allogeneic bone marrow transplant recipients for prevention of graft-versus-host disease (GVHD) and infections, but the minimally effective dose has not been established. In this multicenter, randomized, double-blind trial, patients undergoing allogeneic marrow transplantation were randomized to receive 100 mg/kg, 250 mg/kg, or 500 mg/kg doses of intravenous immunoglobulin. Each dose was given weekly for 90 days and then monthly until 1 year after transplant. Six hundred and eighteen patients were evaluated. Acute GVHD (grades 2-4) occurred in 39% of the patients (80 of 206) in the 100 mg/kg group, 42% of the patients (88 of 208) in the 250 mg/kg group, and in 35% of the patients (72 of 204) in the 500 mg/kg group (P = 0.344). Among patients with unrelated marrow donors, a higher dose of intravenous immunoglobulin (500 mg/kg) was associated with less acute GVHD (P = 0.07). The incidences of chronic GVHD, infection and interstitial pneumonia were similar for all three doses of intravenous immunoglobulin. The dose of intravenous immunoglobulin also had no effect on the types of infection, relapse of hematological malignancy or survival. Except for more frequent chills (P = 0.007) and headaches (P = 0.015) in patients given the 500 mg/kg or 250 mg/kg dose of immunoglobulin, adverse events were similar for all three doses. These results suggest that 100 mg/kg, 250 mg/kg, and 500 mg/kg doses of intravenous immunoglobulin are associated with similar incidences of GVHD and infections in most allogeneic marrow transplants. These results should be considered when designing cost-effective strategies for the use of intravenous immunoglobulin in allogeneic marrow transplants receiving other current regimens for prophylaxis of GVHD and infection.


Subject(s)
Anemia, Aplastic/therapy , Bone Marrow Transplantation/immunology , Graft vs Host Disease/prevention & control , Immunoglobulins, Intravenous/therapeutic use , Infections/epidemiology , Leukemia/therapy , Lymphoma/therapy , Adolescent , Adrenal Cortex Hormones/therapeutic use , Adult , Child , Child, Preschool , Cyclosporine/therapeutic use , Dose-Response Relationship, Drug , Double-Blind Method , Drug Administration Schedule , Female , Graft vs Host Disease/epidemiology , Histocompatibility Testing , Humans , Immunoglobulins, Intravenous/adverse effects , Immunosuppression Therapy/methods , Lymphocyte Depletion , Male , Methotrexate/therapeutic use , Middle Aged , Survival Analysis , Time Factors , Tissue Donors/statistics & numerical data , Transplantation, Homologous
2.
Microb Pathog ; 5(5): 319-32, 1988 Nov.
Article in English | MEDLINE | ID: mdl-2853279

ABSTRACT

T cell hybridomas with specificity for VSV (vesicular stomatitis virus)-infected cells were generated in an attempt to better define the la-restricted helper T cell response to VSV. The hybridomas were created by fusing BALB/c (H-2d) anti-VSV immune spleen cells to the murine thymoma BW 5147. These hybridomas produce IL-2 when stimulated with VSV-infected spleen cells. They were found to recognize viral antigens in association with I-Ad and, in addition, could also be stimulated by VSV-infected A20 cells (an Ia-positive B cell lymphoma of H-2d origin). The purified viral membrane glycoprotein, G protein, and Gs (secreted G protein that lacks the hydrophobic and intracytoplasmic domains) both stimulated IL-2 production when added to cultures of A20 and the hybridomas. These hybridomas therefore recognize a viral antigenic determinant on G protein. Since chemically-fixed antigen-presenting cells fail to stimulate the hybridomas after exogenous addition of purified G protein we can conclude that these T cell hybridomas recognize a processed form of the G protein. Stimulator cells created by expression in A20 of a transfected cDNA encoding G protein were also recognized. Recognition in this case was I-Ad-restricted, as anti-I-Ad monoclonal antibodies blocked stimulation, and an Ia-negative cell (P815) expressing a transfected G protein gene failed to stimulate the hybridomas. Even after paraformaldehyde fixation, G gene-transfected, Ia-positive cells could stimulate the hybridomas, suggesting that processing of this endogenously-synthesized antigen has occurred.


Subject(s)
Genes, MHC Class II , T-Lymphocytes/immunology , Vesicular stomatitis Indiana virus/immunology , Virus Diseases/immunology , Animals , Antigen-Presenting Cells/immunology , Cell Line , Clone Cells , Genes, Viral , Genetic Vectors , Histocompatibility Antigens Class II/immunology , Hybridomas/immunology , Mice , Mice, Inbred BALB C , Restriction Mapping , T-Lymphocytes, Helper-Inducer/immunology , Vesicular stomatitis Indiana virus/genetics , Virus Diseases/genetics
3.
J Natl Cancer Inst ; 72(3): 667-72, 1984 Mar.
Article in English | MEDLINE | ID: mdl-6583449

ABSTRACT

Spleen cells from syngeneic tumor-bearing mice were examined for direct cell-mediated cytotoxicity (DCMC) and lectin-dependent cell-mediated cytotoxicity (LDCC). In the DCMC assay specific cytotoxicity against the homologous tumor cell was assessed. In the LDCC assay cytotoxicity was nonspecifically assessed against EL-4 cells in the presence of concanavalin A or phytohemagglutinin. Most tumor lines tested (19/22) produced no cytotoxic reactivity in either the DCMC or LDCC assays. In the case of the remaining tumor lines (EL-4, BW5147-3, and P815 Y-3), significant LDCC, but not DCMC, was detected, which indicated that although cytotoxic effector cells had been activated, the reactivity was not directed toward the homologous tumor cell or could not be expressed in the DCMC assay. The EL-4 and BW5147-3 cell lines proved to be sporadic in terms of their ability to induce LDCC, whereas the P815 Y-3 cell line produced consistent LDCC. Reactivity induced by P815 Y-3 cells appeared to be due to the constitutive production and release of a soluble component which could activate cytotoxic T-cells in vivo.


Subject(s)
Concanavalin A , Cytotoxicity, Immunologic , Neoplasms, Experimental/immunology , Phytohemagglutinins , Animals , Cell Line , Female , Leukemia, Experimental/immunology , Lymphocyte Activation , Lymphocytes/immunology , Male , Mice , Mice, Inbred C57BL , Mice, Inbred Strains , Neoplasm Transplantation , Species Specificity , Transplantation, Isogeneic
SELECTION OF CITATIONS
SEARCH DETAIL
...